Terho Heikkinen1, Emilia Ojala1, Matti Waris2. 1. Department of Pediatrics, University of Turku and Turku University Hospital. 2. Department of Virology, University of Turku, Finland.
Abstract
BACKGROUND: Vaccines and antivirals against respiratory syncytial virus (RSV) are being developed, but there are scarce data on the full impact of RSV infection on outpatient children. METHODS: We analyzed the burden of RSV illness in a prospective cohort study of children aged ≤13 years during 2 consecutive respiratory seasons in Turku, Finland (2231 child-seasons of follow-up). We examined the children and obtained nasal swabs for the detection of RSV during each respiratory illness. The parents filled out daily symptom diaries throughout the study. RESULTS: Of 6001 medically attended respiratory infections, 302 (5%) were caused by RSV. Per 1000 children, the average annual RSV infection incidence rates among children aged <3, 3-6, and 7-13 years were 275, 117, and 46 cases, respectively. In children aged <3 years, acute otitis media developed in 58%, and 66% of children in this age group received antibiotics. The mean duration of RSV illness was longest (13.0 days) and the rate of parental work absenteeism was highest (136 days per 100 children with RSV illness) in children aged <3 years. CONCLUSIONS: The burden of RSV is particularly great among outpatient children aged <3 years. Young children are an important target group for the development of RSV vaccines and antivirals.
BACKGROUND: Vaccines and antivirals against respiratory syncytial virus (RSV) are being developed, but there are scarce data on the full impact of RSV infection on outpatientchildren. METHODS: We analyzed the burden of RSV illness in a prospective cohort study of children aged ≤13 years during 2 consecutive respiratory seasons in Turku, Finland (2231 child-seasons of follow-up). We examined the children and obtained nasal swabs for the detection of RSV during each respiratory illness. The parents filled out daily symptom diaries throughout the study. RESULTS: Of 6001 medically attended respiratory infections, 302 (5%) were caused by RSV. Per 1000 children, the average annual RSV infection incidence rates among children aged <3, 3-6, and 7-13 years were 275, 117, and 46 cases, respectively. In children aged <3 years, acute otitis media developed in 58%, and 66% of children in this age group received antibiotics. The mean duration of RSV illness was longest (13.0 days) and the rate of parental work absenteeism was highest (136 days per 100 children with RSV illness) in children aged <3 years. CONCLUSIONS: The burden of RSV is particularly great among outpatientchildren aged <3 years. Young children are an important target group for the development of RSV vaccines and antivirals.
Authors: Mari D Takashima; Keith Grimwood; Peter D Sly; Stephen B Lambert; Keith J Chappell; Daniel Watterson; Robert S Ware Journal: Eur J Pediatr Date: 2021-02-25 Impact factor: 3.183
Authors: Jessica L Grieves; Zhiwei Yin; Adolfo Garcia-Sastre; Ignacio Mena; Mark E Peeples; Heidi P Risman; Hannah Federman; Marvin J Sandoval; Russell K Durbin; Joan E Durbin Journal: Vaccine Date: 2018-05-18 Impact factor: 3.641
Authors: Eric A F Simões; Louis Bont; Paolo Manzoni; Brigitte Fauroux; Bosco Paes; Josep Figueras-Aloy; Paul A Checchia; Xavier Carbonell-Estrany Journal: Infect Dis Ther Date: 2018-02-22
Authors: Jim Boonyaratanakornkit; Janet A Englund; Amalia S Magaret; Yunqi Bu; James M Tielsch; Subarna K Khatry; Joanne Katz; Jane Kuypers; Laxman Shrestha; Steven C LeClerq; Mark C Steinhoff; Helen Y Chu Journal: J Pediatric Infect Dis Soc Date: 2020-02-28 Impact factor: 3.164
Authors: Xavier Carbonell-Estrany; Alberto Dall'Agnola; John R Fullarton; Barry S Rodgers-Gray; Elisa Girardi; Alessandro Mussa; Natalia Paniagua; Marta Pieretto; Rosa Rodríguez-Fernandez; Paolo Manzoni Journal: Acta Paediatr Date: 2018-02-12 Impact factor: 2.299
Authors: Jin Gu Yoon; Ji Yun Noh; Won Suk Choi; Jin Ju Park; Yoo Bin Suh; Joon Young Song; Hee Jin Cheong; Woo Joo Kim Journal: Sci Rep Date: 2020-07-21 Impact factor: 4.379